Description General description A cell-permeable thiazolidinedione compound that is shown to inhibit the enzymatic activity of PTP1B, SHP-1, YOP, TC-PTP, and YPTP1 (IC50 = 5, 5.8, 6, 16, and 18 µM, respectively), but not that of LAR even at concentrations as high as 100 µM. Also reported to activate cellular PPAR with an comparable potency seen with troglitazone (Cat. No. 648469). The combined effect of PTP1B inhibition and PPAR activation most likely accounts for the compound′s in vivo antiobesity and antihypoglycemic activity when supplemented directly into the daily high fat diet of C57BL/6j jms Slc male mice (2 mg/g food, ~143 mg/kg animal weight or 4.8 mg/animal). A cell-permeable thiazolidinedione compound that is shown to inhibit the enzymatic activity of PTP1B, SHP-1, YOP, TC-PTP, and YPTP1 (IC50 = 5, 5.8, 6, 16, and 18 µM, respectively), but not that of LAR even at concentrations as high as 100 µM. Also reported to activate cellular PPAR with an comparable potency seen with troglitazone (Cat. No. 648469). The combined effect of PTP1B inhibition and PPAR activation most likely accounts for the compound′s in vivo antiobesity and antihypoglycemic activity when supplemented directly into the daily high fat diet of C57BL/6j jms Slc male mice (2 mg/g food, ~143 mg/kg animal weight or 4.8 mg/animal). Packaging 10 mg in Plastic ampoule Packaged under inert gas Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C. Other Notes Bhattarai, B.R., et al. 2009. Bioorg. Med. Chem. Lett.19, 6161.